Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

<i>Background and Objectives:</i> Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectiveness and safet...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-07-01
Edice:	Medicina
Témata:	alirocumab evolocumab inclisiran hypercholesterolemia proprotein convertase subtilisin/kexin type 9 inhibitors
On-line přístup:	https://www.mdpi.com/1648-9144/60/7/1124
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!